Glycosylated Peptide Market Trends | Industry Size Statistics-2025
Peptide drugs are potential therapeutic agent used against several disease attributing to its features high activity, target specificity, low toxicity, and minimal non-specific or drug–drug interactions. The lower physicochemical properties such as for example poor membrane permeability and low target specific action when administered orally demands for improved peptide drug. Glycosylation of peptides is a promising strategy to modulate the physicochemical properties of peptide drugs and for penetration of peptides across biological membranes. Glycosylation of a peptide may be of two type N-linked glycosylation or O-linked glycosylation. Glycosylation of peptide drug enhances bioactivity, selectivity and prolong half-life of therapeutic drug. Advantages provided by glycosylated peptide over conventional peptide drug are the key factor driving growth of the glycosylated peptide market.
New product launches by the key manufacturers are fueling growth of the Glycosylated Peptide Market. For instance, in 2017, Pfizer Inc., received the U.S. Food and Drug Administration (FDA) approval for Ixifi (infliximab-qbtx), a chimeric human-murine monoclonal antibody, as cure for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Furthermore, in Feb 2017, CT-P10 received approval from the European Commission and in June 2017, it was approved by U.S. FDA. Furthermore, Sumsung Bioepis's Infliximab biosimilar candidate SB2 got Ministry of Food and Drug Safety approval for Korea in 2016, European Commission approval for Europe in 2016.
Comments
Post a Comment